ResearchMoz

Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits

GBI Research
Published Date » 2012-06-25
No. Of Pages » 60
 GBI Research, the leading business intelligence provider, has released its new report Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits. It analyzes the overall Supply Chain Management (SCM) scenario and provides profiles of the leading participants in the pharmaceutical supply chain in the US. The report is built using data and information sourced from proprietary databases, as well as primary and secondary research and in-house analysis by GBI Researchs team of industry experts.  The top three wholesalers in the US, AmerisourceBergen Corporation, Cardinal Health and McKesson Corporation, accounted for 86.7% of the overall US pharmaceutical market in 2011 and combined revenue of $295.2 billion. Various supply chain models are...
Table of Contents

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
2.1 Global Pharmaceutical Companies Changing View of Supply Chain as a Major Driver to Improve Margins and Increase Revenue Growth
2.2 Anti-counterfeiting Technologies such as Radio Frequency Identification to Limit the Introduction of Fake Drugs into the Supply Chain
2.3 Cold-chain Storage to Play Critical Role in the Future Pharmaceutical Supply Chain

3 Pharmaceutical Supply Chain in the US – Introduction
3.1 Report Guidance

4 Pharmaceutical Supply Chain in the US – Introductory Issues
4.1 Evolution of Supply Chain Management
4.2 The Pharmaceutical Supply Chain – Operational Issues
4.2.1 Demand Management with Adequate Forecast Tools to Reduce Inventory Levels
4.2.2 Optimum Inventory Levels Help to Maintain Flow of Working Capital
4.2.3 Supply Chain Performance Visibility in Pharmaceutical Supply Chain Management
4.3 Key Uncertainties in Production Planning and Scheduling
4.3.1 Forecasting Managers have to Deal with the Uncertainty in Demand for Existing Drugs
4.3.2 Uncertainties Experienced by Pipeline Drugs
4.4 Different Supply Chains in Pharmaceutical Industry
4.5 Reverse Logistics Evolving as a Significant Part of the Pharmaceutical Supply Chain
4.6 High Costs Due to Drug Callbacks
4.6.1 Recall Management could Prove Effective if Visibility in the Supply Chain Increases
4.7 Risk Management in Pharmaceutical Supply Chain Management
4.8 Radio Frequency Identification Technology to Play an Important Role in Improving Performance Visibility of the Pharmaceutical Supply Chain

5 Pharmaceutical Supply Chain in the US – Supply Chain Models
5.1 Pharmaceutical Supply Chain Models
5.1.1 Traditional Wholesaler Model
5.1.2 Limited Distribution Model or Specialty Pharmacy Distribution Model
5.1.3 Direct Distribution Model
5.2 Steps to Rationalize Existing Supply Chain
5.3 Cold-chain Storages to Play Critical Role in Supply Chain Management
5.4 Case Study - Implementing Lean Six Sigma to Revamp Pharmaceutical Company Performance

6 Pharmaceutical Supply Chain in the US – Securing a Supply Chain
6.1 Food and Drug Administration’s Role in Addressing Counterfeiting Issues
6.1.1 Case Study: How Counterfeits were Identified at the Border
6.1.2 Case Study: Wholesale Distributor Involved in Diversion Schemes
6.1.3 Case Study: Pharmacies and Pharmacist Involved in Drug Diversion of Samples
6.2 Counterfeiting
6.2.1 Case Study: Fake Cases of Cancer Drug Avastin Raises Issues of Secured Supply Chain Management
6.3 New Technologies Affecting the Performance of the Supply Chain
6.3.1 E-pedigree Track-and-trace Systems
6.3.2 California E-pedigree Implementation Model
6.3.3 Automation of Reports and Consolidated Orders System Reporting
6.3.4 Unique Device Identification for Improving the Traceability of Medical Devices
6.3.5 Radio Frequency Identification, Electronic Product Codes and Physical Mark up Language a Tested Anti-counterfeit Technology
6.4 Anti-counterfeiting Technology Classification
6.5 Overt Technology
6.5.1 Holograms/Diffractive Optical Elements
6.5.2 Optical Variable Device
6.5.3 Sequential Product Numbering
6.5.4 Security Graphics
6.5.5 Product Marking
6.5.6 Color-shifting Security Inks and Films
6.5.7 Film Wrappers
6.5.8 Shrink Seals and Bands
6.5.9 Breakable Caps
6.5.10 Sealed Tubes
6.6 Covet Technologies
6.6.1 Invisible Printing and Watermarks
6.6.2 Hidden Marks and Printing
6.7 Forensic Markers
6.7.1 Chemical Taggants
6.7.2 DNA Fragments
6.7.3 Micro-particle Taggants (Nanotaggants)
6.7.4 Isotope Ratio
6.8 Mass Serialization/Track-and-trace Technologies
6.8.2 Anti-counterfeiting Technologies and their Impact on Pharmaceutical Companies
6.9 Case Study: Sproxil to Benefit from Mobile Technology
6.10 Top Anti-counterfeiting Companies and their Innovative Technologies
6.10.1 Reed-Lane, Inc
6.10.2 Cortegra Group Inc
6.10.3 Nanolnk Inc
6.10.4 TraceLink Inc
6.10.5 Axway
6.10.6 Innovatum Inc
6.10.7 Vetter Pharma International GmbH

7 Pharmaceutical Supply Chain in the US – Legislative Specifications of Pharmaceutical Traceability Enhancement Code Act
7.1 Title l: Immediate Provisions to Enhance Patient Safety
7.2 Title ll: Development of RxTEC System
7.3 Title lll: Enhanced FDA and State Authorities
7.4 Title lV: RxTEC System Assessment
7.5 Title V: Uniform National Policy

8 Pharmaceutical Supply Chain in the US – Wholesale Sector
8.1 Market Leaders in the Wholesale Sector
8.2 Trends Seen Across the US Wholesale Industry
8.3 Prescription Drug Marketing Act of 1987
8.4 Market Share of Wholesalers
8.5 McKesson
8.5.1 Company Profile
8.6 AmerisourceBergen
8.6.1 Company Profile
8.7 Cardinal Health Inc
8.7.1 Company Profile

9 Pharmaceutical Supply Chain in the US – Pharmacy Sector
9.1 The US Pharmacy Sector
9.2 Market Share of Different Channels in the US Pharmaceutical Supply Chain
9.3 Market Share of Top Three Chain Drug Stores in the US

10 Pharmaceutical Supply Chain in the US – Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Primary Research
10.4.4 Expert Panel Validation
10.5 Contact Us
10.6 Disclaimer

List of Tables


Table 1: Pharmaceutical Supply Chain in the US, Storage and Handling Regimes of Blockbuster Products, 2012 25
Table 2: Pharmaceutical Supply Chain in the US, Advantages and Disadvantages of Overt Features, 2012 36
Table 3: Pharmaceutical Supply Chain in the US, Advantages and Disadvantages of Covert Features, 2012 37
Table 4: Pharmaceutical Supply Chain in the US, Advantages and Disadvantages of Forensic Markers 38
Table 5: Pharmaceutical Supply Chain in the US, Advantages and Disadvantages of Track-and-trace Technologies, 2012 39

List of Figures


Figure 1: Pharmaceutical Supply Chain in the US, Evolution of Supply Chain Management, 2011 11
Figure 2: Pharmaceutical Supply Chain in the US, Implementation of Lean Supply Chain Management, 2011 12
Figure 3: Pharmaceutical Supply Chain in the US, Key Uncertainties Faced by Manufacturers, 2012 14
Figure 4: Pharmaceutical Supply Chain in the US, Number of Drug Callbacks, 2006-2011 16
Figure 5: Pharmaceutical Supply Chain in the US, Impact of Vioxx Withdrawal on Mercks Share Prices, January 2003December 2005 17
Figure 6: Pharmaceutical Supply Chain in the US, Risk Management Benefits, 2012 18
Figure 7: Pharmaceutical Supply Chain in the US, Risk Evaluation Procedure, 2012 19
Figure 8: Pharmaceutical Supply Chain in the US, Working of Radio Frequency Identification Technology, 2012 20
Figure 9: Pharmaceutical Supply Chain in the US, Structure of a Traditional Distribution Channel, 2012 21
Figure 10: Pharmaceutical Supply Chain in the US, Structure of a Limited Distribution Channel, 2012 22
Figure 11: Pharmaceutical Supply Chain in the US, Structure of a Direct-to-pharmacy Distribution Channel, 2011 23
Figure 12: Pharmaceutical Supply Chain in the US, Cold-chain Storage Forecast, $bn, 2011-2016 26
Figure 13: Pharmaceutical Supply Chain in the US, Counterfeit Drugs Identified, 2011 27
Figure 14: Pharmaceutical Supply Chain in the US, Wholesale Distributor Involved in Diversion Schemes, 2011 28
Figure 15: Pharmaceutical Supply Chain in the US, Pharmacies and Pharmacist Involved in Drug Diversion of Samples, 2011 29
Figure 16: Pharmaceutical Supply Chain in the US, Types of Trades Associated with Suspected Counterfeits, (%), 2011 30
Figure 17: Pharmaceutical Supply Chain in the US, Counterfeit Avastin Case Study, 2012 31
Figure 18: Pharmaceutical Supply Chain in the US, E-pedigree in a Pharmaceutical Supply Chain, 2012 32
Figure 19: Pharmaceutical Supply Chain in the US, Paper-based Pedigree in a Pharmaceutical Supply Chain, 2011 33
Figure 20: Pharmaceutical Supply Chain in the US, California E-pedigree Implementation Model, The US, 2012 34
Figure 21: Pharmaceutical Supply Chain in the US, Classification of Anti-counterfeit Technologies, 2012 35
Figure 22: Pharmaceutical Supply Chain in the US, Platform for Protecting Pharmaceutical Value Chain, 2012 40
Figure 23: Pharmaceutical Supply Chain in the US, Company Overview, Reed-Lane Inc, 2012 41
Figure 24: Pharmaceutical Supply Chain in the US, Company Overview, Cortegra Group Inc, 2012 42
Figure 25: Pharmaceutical Supply Chain in the US, Company Overview, NanoInk Inc, 2012 43
Figure 26: Pharmaceutical Supply Chain in the US, Company Overview, TraceLink, 2012 44
Figure 27: Pharmaceutical Supply Chain in the US, Company Overview, Axway, 2012 45
Figure 28: Pharmaceutical Supply Chain in the US, Company Overview, Innovatum Inc, 2012 46
Figure 29: Pharmaceutical Supply Chain in the US, Company Overview, Vetter Pharma International GmbH, 2012 47
Figure 30: Pharmaceutical Supply Chain in the US, Market Share of Wholesalers, (%), 2011 50
Figure 31: Pharmaceutical Supply Chain in the US, Company Profile, McKesson, 2011 51
Figure 32: Pharmaceutical Supply Chain in the US, Company Profile, AmerisourceBergen, 2011 52
Figure 33: Pharmaceutical Supply Chain in the US, Company Profile, Cardinal Health Inc, 2011 53
Figure 34: Pharmaceutical Supply Chain in the US, Market Share of Different Prescription-dispensing Channels, (%), 2011 54
Figure 35: Pharmaceutical Supply Chain in the US, Market Share of Top Three Chain Drug Stores, 2012 55

Upcoming Reports:

Poland: calcium fertilizers market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the calcium fertilizers market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the calcium fertilizers market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate...
ADME Toxicology Testing Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
ADME is the process of absorption, distribution, metabolism and elimination of chemicals or drugs that describe their disposition inside a human body. The four processes influence the performance of a particular drug toward human tissues; toxicology testing before introducing a particular drug is increasingly becoming important. For the development of a new drug, ADME toxicology testing is being adopted at a rapid rate by all pharmaceutical and biotechnology companies to reduce their drug discovery, testing and development costs. The ADME toxicology testing market has been categorized in...
Greece: market of iron or steel tanks, casks, drums and cans
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the iron or steel tanks, casks, drums and cans market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the iron or steel tanks, casks, drums and cans market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Order cancellations not a sign of market slump: Airbus
Jul 31, 2014  
Leading aircraft manufacturer Airbus on Wednesday said that the recent wave of order cancellations for its commercial jetliners do not mean that the market has declined. The market is still strong and single-aisle jets deals are likely to return later. A total of 225 Airbus cancellations were reported since the beginning of this year. Of these, Dubai’s Emirates Airlines alone...
Leading Australian Universities Want to Hike Fees, Enroll Fewer Students
Jul 31, 2014  
Australia’s prestigious group of top eight universities, also known as the Group of Eight (Go8), has indicated plans of increasing tuition fees while reducing the number of students they enroll, a reform-backer has predicted. These decisions could be made if the universities are deregulated .  Arguing for this decision, the chairman of Go8, and vice chancellor of the ANU, Ian...
Blackstone Invests $800 Million in Asian Oil-Based Energy Company
Jul 31, 2014  
Blackstone Energy Partners announced to invest $800 million in an Asian based energy company that is led by former industry executives.  Blackstone is popularly considered a part of the world’s largest administrator of alternatives to financial stocks and bonds. New York-based managing director, Angelo Acconcia of Blackstone Energy Partners said in an interview that Tamarind...
Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...